AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

AstraZeneca said that about 20% of patients treated with the Stride regimen, which is a single dose of Imjudo added to Imfinzi, were alive at five years, compared to 9.4% of those treated with ...

In a result that's likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside chemotherapy and surgery. Two years after ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...